2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991156
    Rapaprutug
    		Ligand
    Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases.
    Rapaprutug
  • HY-128553A
    (Rac)-Antineoplaston A10
    		Inhibitor
    (rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
    (Rac)-Antineoplaston A10
  • HY-142947
    KRAS G12C inhibitor 45
    		Inhibitor
    KRAS G12C inhibitor 45 (compound 78) is a potent KRAS G12C inhibitor.
    KRAS G12C inhibitor 45
  • HY-112492
    KRas G12C inhibitor 2
    		Inhibitor
    KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 2
  • HY-152145
    PROTAC SOS1 degrader-3
    		Inhibitor
    PROTAC SOS1 degrader-3 is a potent PROTAC SOS1 degrader. PROTAC SOS1 degrader-3 effectively targeted SOS1 for degradation through the ubiquitin-proteasome system.
    PROTAC SOS1 degrader-3
  • HY-161634
    PROTAC SOS1 degrader-8
    		Degrader
    PROTAC SOS1 degrader-8 (Compd 1) is a PROTAC-based SOS1 degrader (Red: SOS1 Ligand (HY-161635), Black: linker (HY-W056267), Blue: E3 ligase ligand (HY-161637)).
    PROTAC SOS1 degrader-8
  • HY-168442
    KRAS inhibitor-40
    		Inhibitor
    KRAS inhibitor-40 (Compound 41) is a KRAS inhibitor that interferes with the KRAS G12C-BRAF complex. KRAS inhibitor-40 inhibits the ERK phosphorylation of KRAS downstream signaling pathway. KRAS inhibitor-40 can inhibit the proliferation of tumor cells with different KRAS mutation types and has antitumor activity.
    KRAS inhibitor-40
  • HY-151288
    KRAS inhibitor-21
    		Inhibitor
    KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC50 value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research.
    KRAS inhibitor-21
  • HY-162974
    KRAS inhibitor-34
    		Inhibitor
    KRAS inhibitor-34 (compound 27) is a KRAS inhibitor, with IC50 of 6.4 nM. KRAS inhibitor-34 can be used in tumor research.
    KRAS inhibitor-34
  • HY-158008
    (R)-G12Di-7
    		Inhibitor
    (R)-G12Di-7 is a covalent ligand for KRAS-G12D, which selectively labels K-Ras-G12D·GDP and K-Ras-G12D·GppNHp. (R)-G12Di-7 exhibits inhibitory activity against G12D mutated cancer cells.
    (R)-G12Di-7
  • HY-118426
    (Rac)-Tipifarnib
    (Rac)-Tipifarnib ((Rac)-IND 58359; (Rac)-R115777) is a potent farnesyl protein transferase inhibitor that specifically targets the pro-tailation process of Ras proteins. (Rac)-Tipifarnib showed significant in vivo antitumor effects after oral administration to mice.
    (Rac)-Tipifarnib
  • HY-153177
    PAT-IN-2
    		Inhibitor
    PAT-IN-2 is a protein acyl transferases (PAT) inhibitor. PAT-IN-2 competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 25).
    PAT-IN-2
  • HY-162444
    KRAS G12D inhibitor 22
    		Inhibitor
    KRAS G12D inhibitor 22 (compound 6) is a inhibitor of KRAS mutation. KRAS G12D inhibitor 22 has high activity (IC50＜100 nM), good selectivity and low toxicity.KRAS G12D inhibitor 22 can be used in breast cancer research.
    KRAS G12D inhibitor 22
  • HY-175341
    Rac1-IN-5
    		Inhibitor
    Rac1-IN-5 is a specific, reversible inhibitor of RAC1 (KD = 30 nM). Rac1-IN-5 competes with guanine nucleotides for specific binding to RAC proteins, effectively blocking RAC1 activity and RAC1-dependent cellular functions. Rac1-IN-5 exhibits anti-tumor metastasis effects in vivo and can improve survival. Rac1-IN-5 can be used to study invasive cancers such as triple-negative breast cancer and colon cancer.
    Rac1-IN-5
  • HY-163636
    Deltaflexin3
    		Inhibitor
    Deltaflexin3 is a potent PDE6D inhibitor. Deltaflexin3 reduces the signaling of Ras and selectively decreases the KRAS mutant and PDE6D-dependent cancer cells growth.
    Deltaflexin3
  • HY-153176
    PAT-IN-1
    		Inhibitor
    PAT-IN-1 is a protein acyl transferases (PAT) inhibitor. PAT-IN-1 competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13).
    PAT-IN-1
  • HY-170327
    ZCL279
    		Inhibitor
    ZCL279 is a small molecule modulator (SMM) that inhibits Cdc42-intersectin (ITSN) interaction. ZCL279 can activate Cdc42 (a cytoplasmic small GTPase in the Ras superfamily) at lower concentrations (<10 μM) and significantly inhibit it at higher concentrations (<10 μM).
    ZCL279
  • HY-143607
    KRAS G12D inhibitor 13
    		Inhibitor
    KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142).
    KRAS G12D inhibitor 13
  • HY-145737
    PROTAC SOS1 degrader-1
    		Agonist
    PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity.
    PROTAC SOS1 degrader-1
  • HY-164749
    K-Ras-IN-4
    		Inhibitor
    K-Ras-IN-4 (compund CP163) is a K-Ras inhibitor.
    K-Ras-IN-4
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.